Effect of Variable Doses of Metronidazole in Treatment of Helicobacterpylori

Phase 3

• Conditions: Helicobacter pylori Infection.; Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere; B96.81

• Registration Number: IRCT20211012052740N1
• Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

Dyspeptic Patients with Positive Helicobacterpylori Stool Antigen Test
Older than 18 Years Old Persons

Exclusion Criteria

No Referring After Taking the Medication
Taking Medications for Less than 10 Days
Pregnant or Breastfeeding Women
Patients with the History of Major Cardiac, Pulmonary, Renal or Hepatic Disease
History of Known Side Effects to the Medications of Therapeutic Regimen
Taking Antibiotic during the Last Month

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradication of Helicobacter pylori Infection. Timepoint: Four Weeks after the Termination of Treatment. Method of measurement: Helicobacter pylori Stool Antigen Test.

Secondary Outcome Measures

Name	Time	Method
Drug Adverse Effects Including: Nausa, Abdominal Pain, Metallic Taste, Diarrhea. Timepoint: Four Weeks after Starting the Treatment. Method of measurement: Questionnaire.;The Tolerance to Accepting the Treatment (Taking Medications more than 10 Days). Timepoint: Two Weeks after Starting the Treatment. Method of measurement: Questionnaire.